» Articles » PMID: 35536451

Identification of a 5-gene-risk Score Model for Predicting Luminal A-invasive Lobular Breast Cancer Survival

Overview
Journal Genetica
Specialties Cell Biology
Genetics
Date 2022 May 10
PMID 35536451
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is a devastating malignancy, among which the luminal A (LumA) breast cancer is the most common subtype. In the present study, we used a comprehensive bioinformatics approach in the hope of identifying novel prognostic biomarkers for LumA breast cancer patients. Transcriptomic profiling of 611 LumA breast cancer patients was downloaded from TCGA database. Differentially expressed genes (DEGs) between tumor samples and controls were first identified by differential expression analysis, before being used for the weighted gene co-expression network analysis. The subsequent univariate Cox regression and LASSO algorithm were used to uncover key prognostic genes for constructing multivariate Cox regression model. Patients were stratified into high-risk and low-risk groups according to the risk score, and subjected to multiple downstream analyses including survival analysis, gene set enrichment analysis (GSEA), inference on immune cell infiltration and analysis of mutation burden. Receiving operator curve analysis was also performed. A total of 7071 DEGs were first identified by edgeR package, pink module was found significantly associated with invasive lobular carcinoma (ILC). 105 prognostic genes and 9 predictors were identified, allowing the identification of a 5-key prognostic genes (LRRC77P, CA3, BAMBI, CABP1, ATP8A2) after intersection. These 5 genes, and the resulting Cox model, displayed good prognostic performance. Furthermore, distinct differences existed between two risk-score stratified groups at various levels. The identified 5-gene prognostic model will help deepen the understanding of the molecular and immunological mechanisms that affect the survival of LumA-ILC patients and guide and proper monitoring of these patients.

Citing Articles

Type IV P-Type ATPases: Recent Updates in Cancer Development, Progression, and Treatment.

Yazlovitskaya E, Graham T Cancers (Basel). 2023; 15(17).

PMID: 37686603 PMC: 10486736. DOI: 10.3390/cancers15174327.


Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma.

Miroschnikov N, Drager O, Van Meenen D, Metz K, Budeus B, Dunker N J Oncol. 2023; 2023:2270097.

PMID: 36993823 PMC: 10042642. DOI: 10.1155/2023/2270097.

References
1.
Astashchanka A, Shroka T, Jacobsen B . Mucin 2 (MUC2) modulates the aggressiveness of breast cancer. Breast Cancer Res Treat. 2018; 173(2):289-299. PMC: 6813790. DOI: 10.1007/s10549-018-4989-2. View

2.
Banerjee A, Wu Z, Qian P, Kang J, Pandey V, Liu D . ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma. Breast Cancer Res. 2011; 13(6):R112. PMC: 3326554. DOI: 10.1186/bcr3054. View

3.
Bar-Mashiah A, Soper E, Cullina S, Belbin G, Kenny E, Lucas A . CDH1 pathogenic variants and cancer risk in an unselected patient population. Fam Cancer. 2021; 21(2):235-239. PMC: 8531152. DOI: 10.1007/s10689-021-00257-x. View

4.
Bates G, Fox S, Han C, Leek R, Garcia J, Harris A . Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34):5373-80. DOI: 10.1200/JCO.2006.05.9584. View

5.
Bianchini G, Qi Y, Alvarez R, Iwamoto T, Coutant C, Ibrahim N . Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010; 28(28):4316-23. DOI: 10.1200/JCO.2009.27.2419. View